QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...

The US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, ...

Qiagen stock faces market pressure due to recent NIH funding concerns, despite strong financials and a diverse product portfolio. Click to read why QGEN is a Hold.

For many investors, the main point of stock picking is to generate higher returns than the overall market. But the ...

New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN’s growing U.S. menu for syndromic testing of gastrointestinal ...

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...

Shares of Qiagen (NYSE:QGEN – Get Free Report) have been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Seven equities ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...